Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis

Giuseppe Scalabrino, Daniela Galimberti, Elena Mutti, Diego Scalabrini, Daniela Veber, Milena De Riz, Fabrizia Bamonti, Elisabetta Capello, Giovanni Luigi Mancardi, Elio Scarpini

Research output: Contribution to journalArticle

Abstract

We investigated whether the physiological regulation of cerebrospinal fluid (CSF) levels of tumor necrosis factor (TNF)-α, epidermal growth factor (EGF), and nerve growth factor (NGF) by cobalamin (Cbl) that is observed in rat and human central nervous system (CNS) is retained in the CSF of patients with multiple sclerosis (MS). The study involved 158 MS patients grouped on the basis of the different clinical courses (relapsing-remitting (RR), secondary-progressive (SP), and primary-progressive (PP)), and 76 gender- and age-matched control patients with other non-inflammatory and non-neoplastic neurological diseases. The MS patients were therapy-free at the time of lumbar puncture. CSF Cbl and EGF were blindly measured by means of radioimmunoassays, and CSF TNF-α, and NGF by means of highly sensitive enzyme-linked immunosorbent assays. Serum EGF was also measured in 38 of the MS patients and 20 healthy controls. CSF Cbl levels were significantly higher (RR patients 27.9 ± 9.7 pg/ml, p <0.0001 vs. C; SP patients 25.4 ± 8 pg/ml, p <0.02 vs. C), and CSF TNF-α and EGF levels significantly lower in the patients with the RR (TNF-α 28.3 ± 23.4 × 10 -3 pg/ml, p <0.0001 vs. C; EGF 129.9 ± 44.8 pg/ml, p <0.02 vs. C) or SP (TNF-α 20.5 ± 20.5 × 10 -3 pg/ml, p <0.001 vs. C; EGF 116.5 ± 24.8 pg/ml, p <0.05 vs. C) clinical course than in controls (Cbl 21 ± 4.6 pg/ml; TNF-α 75.6 ± 34.7 × 10 -3 pg/ml; EGF 170.2 ± 54.8 pg/ml). There were no differences in CSF NGF or serum EGF levels between any of the MS clinical courses and controls. Our results indicate that: (a) the positive Cbl-mediated regulation of myelino- and oligodendrocyte-trophic EGF is lost in the CSF of RR- or SP-MS patients; (b) the decrease in EGF levels in the CSF may be one factor impeding CNS remyelination in MS; and (c) the PP clinical course may have different pathogenetic mechanism(s) also on the basis of the molecules investigated in this study.

Original languageEnglish
Pages (from-to)64-71
Number of pages8
JournalBrain Research
Volume1333
DOIs
Publication statusPublished - May 28 2010

Fingerprint

Vitamin B 12
Epidermal Growth Factor
Multiple Sclerosis
Cerebrospinal Fluid
Tumor Necrosis Factor-alpha
Nerve Growth Factor
Chronic Progressive Multiple Sclerosis
Central Nervous System
Spinal Puncture
Oligodendroglia
Serum
Radioimmunoassay
Enzyme-Linked Immunosorbent Assay

Keywords

  • Cerebrospinal fluid
  • Cobalamin
  • Epidermal growth factor
  • Multiple sclerosis
  • Nerve growth factor
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. / Scalabrino, Giuseppe; Galimberti, Daniela; Mutti, Elena; Scalabrini, Diego; Veber, Daniela; De Riz, Milena; Bamonti, Fabrizia; Capello, Elisabetta; Mancardi, Giovanni Luigi; Scarpini, Elio.

In: Brain Research, Vol. 1333, 28.05.2010, p. 64-71.

Research output: Contribution to journalArticle

Scalabrino, G, Galimberti, D, Mutti, E, Scalabrini, D, Veber, D, De Riz, M, Bamonti, F, Capello, E, Mancardi, GL & Scarpini, E 2010, 'Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis', Brain Research, vol. 1333, pp. 64-71. https://doi.org/10.1016/j.brainres.2010.03.073
Scalabrino, Giuseppe ; Galimberti, Daniela ; Mutti, Elena ; Scalabrini, Diego ; Veber, Daniela ; De Riz, Milena ; Bamonti, Fabrizia ; Capello, Elisabetta ; Mancardi, Giovanni Luigi ; Scarpini, Elio. / Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. In: Brain Research. 2010 ; Vol. 1333. pp. 64-71.
@article{a5f59c95062c462b8e09f715f755bfac,
title = "Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis",
abstract = "We investigated whether the physiological regulation of cerebrospinal fluid (CSF) levels of tumor necrosis factor (TNF)-α, epidermal growth factor (EGF), and nerve growth factor (NGF) by cobalamin (Cbl) that is observed in rat and human central nervous system (CNS) is retained in the CSF of patients with multiple sclerosis (MS). The study involved 158 MS patients grouped on the basis of the different clinical courses (relapsing-remitting (RR), secondary-progressive (SP), and primary-progressive (PP)), and 76 gender- and age-matched control patients with other non-inflammatory and non-neoplastic neurological diseases. The MS patients were therapy-free at the time of lumbar puncture. CSF Cbl and EGF were blindly measured by means of radioimmunoassays, and CSF TNF-α, and NGF by means of highly sensitive enzyme-linked immunosorbent assays. Serum EGF was also measured in 38 of the MS patients and 20 healthy controls. CSF Cbl levels were significantly higher (RR patients 27.9 ± 9.7 pg/ml, p <0.0001 vs. C; SP patients 25.4 ± 8 pg/ml, p <0.02 vs. C), and CSF TNF-α and EGF levels significantly lower in the patients with the RR (TNF-α 28.3 ± 23.4 × 10 -3 pg/ml, p <0.0001 vs. C; EGF 129.9 ± 44.8 pg/ml, p <0.02 vs. C) or SP (TNF-α 20.5 ± 20.5 × 10 -3 pg/ml, p <0.001 vs. C; EGF 116.5 ± 24.8 pg/ml, p <0.05 vs. C) clinical course than in controls (Cbl 21 ± 4.6 pg/ml; TNF-α 75.6 ± 34.7 × 10 -3 pg/ml; EGF 170.2 ± 54.8 pg/ml). There were no differences in CSF NGF or serum EGF levels between any of the MS clinical courses and controls. Our results indicate that: (a) the positive Cbl-mediated regulation of myelino- and oligodendrocyte-trophic EGF is lost in the CSF of RR- or SP-MS patients; (b) the decrease in EGF levels in the CSF may be one factor impeding CNS remyelination in MS; and (c) the PP clinical course may have different pathogenetic mechanism(s) also on the basis of the molecules investigated in this study.",
keywords = "Cerebrospinal fluid, Cobalamin, Epidermal growth factor, Multiple sclerosis, Nerve growth factor, Tumor necrosis factor-α",
author = "Giuseppe Scalabrino and Daniela Galimberti and Elena Mutti and Diego Scalabrini and Daniela Veber and {De Riz}, Milena and Fabrizia Bamonti and Elisabetta Capello and Mancardi, {Giovanni Luigi} and Elio Scarpini",
year = "2010",
month = "5",
day = "28",
doi = "10.1016/j.brainres.2010.03.073",
language = "English",
volume = "1333",
pages = "64--71",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis

AU - Scalabrino, Giuseppe

AU - Galimberti, Daniela

AU - Mutti, Elena

AU - Scalabrini, Diego

AU - Veber, Daniela

AU - De Riz, Milena

AU - Bamonti, Fabrizia

AU - Capello, Elisabetta

AU - Mancardi, Giovanni Luigi

AU - Scarpini, Elio

PY - 2010/5/28

Y1 - 2010/5/28

N2 - We investigated whether the physiological regulation of cerebrospinal fluid (CSF) levels of tumor necrosis factor (TNF)-α, epidermal growth factor (EGF), and nerve growth factor (NGF) by cobalamin (Cbl) that is observed in rat and human central nervous system (CNS) is retained in the CSF of patients with multiple sclerosis (MS). The study involved 158 MS patients grouped on the basis of the different clinical courses (relapsing-remitting (RR), secondary-progressive (SP), and primary-progressive (PP)), and 76 gender- and age-matched control patients with other non-inflammatory and non-neoplastic neurological diseases. The MS patients were therapy-free at the time of lumbar puncture. CSF Cbl and EGF were blindly measured by means of radioimmunoassays, and CSF TNF-α, and NGF by means of highly sensitive enzyme-linked immunosorbent assays. Serum EGF was also measured in 38 of the MS patients and 20 healthy controls. CSF Cbl levels were significantly higher (RR patients 27.9 ± 9.7 pg/ml, p <0.0001 vs. C; SP patients 25.4 ± 8 pg/ml, p <0.02 vs. C), and CSF TNF-α and EGF levels significantly lower in the patients with the RR (TNF-α 28.3 ± 23.4 × 10 -3 pg/ml, p <0.0001 vs. C; EGF 129.9 ± 44.8 pg/ml, p <0.02 vs. C) or SP (TNF-α 20.5 ± 20.5 × 10 -3 pg/ml, p <0.001 vs. C; EGF 116.5 ± 24.8 pg/ml, p <0.05 vs. C) clinical course than in controls (Cbl 21 ± 4.6 pg/ml; TNF-α 75.6 ± 34.7 × 10 -3 pg/ml; EGF 170.2 ± 54.8 pg/ml). There were no differences in CSF NGF or serum EGF levels between any of the MS clinical courses and controls. Our results indicate that: (a) the positive Cbl-mediated regulation of myelino- and oligodendrocyte-trophic EGF is lost in the CSF of RR- or SP-MS patients; (b) the decrease in EGF levels in the CSF may be one factor impeding CNS remyelination in MS; and (c) the PP clinical course may have different pathogenetic mechanism(s) also on the basis of the molecules investigated in this study.

AB - We investigated whether the physiological regulation of cerebrospinal fluid (CSF) levels of tumor necrosis factor (TNF)-α, epidermal growth factor (EGF), and nerve growth factor (NGF) by cobalamin (Cbl) that is observed in rat and human central nervous system (CNS) is retained in the CSF of patients with multiple sclerosis (MS). The study involved 158 MS patients grouped on the basis of the different clinical courses (relapsing-remitting (RR), secondary-progressive (SP), and primary-progressive (PP)), and 76 gender- and age-matched control patients with other non-inflammatory and non-neoplastic neurological diseases. The MS patients were therapy-free at the time of lumbar puncture. CSF Cbl and EGF were blindly measured by means of radioimmunoassays, and CSF TNF-α, and NGF by means of highly sensitive enzyme-linked immunosorbent assays. Serum EGF was also measured in 38 of the MS patients and 20 healthy controls. CSF Cbl levels were significantly higher (RR patients 27.9 ± 9.7 pg/ml, p <0.0001 vs. C; SP patients 25.4 ± 8 pg/ml, p <0.02 vs. C), and CSF TNF-α and EGF levels significantly lower in the patients with the RR (TNF-α 28.3 ± 23.4 × 10 -3 pg/ml, p <0.0001 vs. C; EGF 129.9 ± 44.8 pg/ml, p <0.02 vs. C) or SP (TNF-α 20.5 ± 20.5 × 10 -3 pg/ml, p <0.001 vs. C; EGF 116.5 ± 24.8 pg/ml, p <0.05 vs. C) clinical course than in controls (Cbl 21 ± 4.6 pg/ml; TNF-α 75.6 ± 34.7 × 10 -3 pg/ml; EGF 170.2 ± 54.8 pg/ml). There were no differences in CSF NGF or serum EGF levels between any of the MS clinical courses and controls. Our results indicate that: (a) the positive Cbl-mediated regulation of myelino- and oligodendrocyte-trophic EGF is lost in the CSF of RR- or SP-MS patients; (b) the decrease in EGF levels in the CSF may be one factor impeding CNS remyelination in MS; and (c) the PP clinical course may have different pathogenetic mechanism(s) also on the basis of the molecules investigated in this study.

KW - Cerebrospinal fluid

KW - Cobalamin

KW - Epidermal growth factor

KW - Multiple sclerosis

KW - Nerve growth factor

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=77952322955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952322955&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2010.03.073

DO - 10.1016/j.brainres.2010.03.073

M3 - Article

C2 - 20347721

AN - SCOPUS:77952322955

VL - 1333

SP - 64

EP - 71

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -